VALLEY COTTAGE, New York, February 15, 2017 /PRNewswire/ --
Russia's healthcareinfrastructure will continue witnessing significant rise in number of orthopaedic patients as several bone & joint-related disorders are likely to be caused by people's eating & drink habits, their proactive lifestyles and the country's harsh
(Logo: http://photos.prnewswire.com/prnh/20161020/430874LOGO )
Request a Sample Report with Table of Contents: http://www.futuremarketinsights.com/reports/sample/rep-ru-2897
According to Future Market Insights' recent report, titled "Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026," nearly 70% of viscosupplementation revenues amassed across Russia in 2016 were accounted by three-injection viscosupplementation. The report estimates that the Russian viscosupplementation market incurred revenues worth over RUB 1.13 billion (US$ 19 million) in 2016. Registering a steady increment at 5.3% CAGR, Russia's viscosupplementation revenues are expected to reach RUB 2.02 billion (US$ 34 million) by the end of 2026. With higher demand for three-injection viscosupplementation, Russia's healthcare industry leaders will continue to extend production of three-injection viscosupplementation products as opposed to single injection and five-injection viscosupplementation products.
The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia's ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026.
Preview Analysis on Russia Viscosupplementation Market Segmentation By Product Type - Single Injection, Three Injection, Five Injection Viscosupplementation; By End Use - Hospitals (500+ Bedded, 250-500 Bedded, Less Than 250 Bedded), Ambulatory Surgical Centres, Orthopaedic Clinics: http://www.futuremarketinsights.com/reports/russia-viscosupplementation-market
Top Players in Russia's Viscosupplementation Market
Top three established players in Russia's Viscosupplementation market include Hyaltech, Croma-Pharma GmbH and TRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country's viscosupplementation revenues. International players such as Sanofi, Ferring Pharmaceuticals and Fidia Farmaceutici spa have low share as compared to the other players, Anika Therapeutics has recently launched their viscosupplementation product in Russia's viscosupplementation market.
More From FMI's Cutting-edge Intelligence:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.
Browse More Healthcare, Pharmaceuticals and Medical devices Market Insights
Contact Us 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 F: +1-845-579-5705 T (UK): + 44-(0)-20-7692-8790 Sales: email@example.com Press Office: Press@futuremrketinsights.com
SOURCE Future Market Insights
Subscribe to our Free Newsletters!